Putting the 87 scSTAR-C2 marker genes and the 100 scSTAR-C1 marker genes in CD8+ T cells, the 299 scSTAR-C3 marker genes and the 61 scSTAR-C2 marker genes in CD4+ T cells, the 91 scSTAR-C2 marker genes and the 70 scSTAR-C3 marker genes in B cells into Kaplan-Meier survival analysis for pan-cancer revealed that ATHENA not only increased the proportion of superior prognosis but also decreased the proportion of inferior prognosis. The gene discussed is CD8A; the disease is cancer.